激活自然杀伤T细胞增强调节性T细胞疗法抑制小鼠GVHD
本研究在小鼠GVHD模型中证实,单次给予α-半乳糖神经酰胺脂质体(α-GalCer-lipo)可增强过继转移后Treg的体内扩增,并提升Treg疗法的疗效,即使注射原本次优的细胞数量。宿主而非供体iNKT细胞是抑制GVHD所必需的。iNKT细胞激活与Treg过继治疗联合可能使Treg疗法更可行、更安全。
要点
- α-GalCer-lipo单次给药增强Treg过继转移后的体内扩增。
- 联合iNKT激活可提升次优数量Treg的疗效。
- GVHD抑制依赖宿主iNKT细胞而非供体iNKT细胞。
核心结论
- iNKT细胞激活联合Treg过继治疗可增强疗效并减少所需Treg数量,使疗法更可行安全。
研究设计与样本
- 小鼠GVHD模型研究,比较α-GalCer-lipo给药后Treg过继转移的体内扩增与疗效。
- 使用WT C57BL/6与Jα18-/- iNKT细胞缺陷BALB/c小鼠进行供受体组合移植实验。
主要发现
- 单次α-GalCer-lipo给药增强Treg过继转移后的体内扩增。
- 联合治疗提升Treg疗法疗效,即使注射原本次优的细胞数量。
- WT C57BL/6供体至Jα18-/- BALB/c受体未显示α-GalCer-lipo生存获益,而Jα18-/-供体至WT受体显示获益。
临床怎么用
- 联合iNKT激活可能降低Treg疗法所需细胞数量,提升可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cellular therapy with regulatory T cells (Tregs) has shown promising results for suppressing graft-versus-host disease (GVHD) while preserving graft vs tumor effects in animal models and phase 1/2 clinical trials. However, a paucity of Tregs in the peripheral blood makes it difficult to acquire sufficient numbers of cells and hampers further clinical application. Invariant natural killer T (iNKT) cells constitute another compartment of regulatory cells that ameliorate GVHD through activation of Tregs after their own activation with α-galactosylceramide (α-GalCer) or adoptive transfer. We demonstrate here that a single administration of α-GalCer liposome (α-GalCer-lipo) enhanced the in vivo expansion of Tregs after adoptive transfer in a murine GVHD model and improved therapeutic efficacy of Treg therapy even after injection of otherwise suboptimal cell numbers. Host iNKT cells rather than donor iNKT cells were required for GVHD suppression because the survival benefit of α-GalCer-lipo administration was not shown in the transplantation of cells from wild-type (WT) C57BL/6 mice into Jα18-/- iNKT cell-deficient BALB/c mice, whereas it was observed from Jα18-/- C57BL/6 donor mice into WT BALB/c recipient mice. The combination of iNKT cell activation and Treg adoptive therapy may make Treg therapy more feasible and safer by enhancing the efficacy and reducing the number of Tregs required.
引用
- Hirai T, Lin PY, Simonetta F, et al. Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD. Blood Adv. 2021. PMID: 34100904. doi:10.1182/bloodadvances.2020003272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。